Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 4, 2013, Pages 220-224

  Hu, S H ^a   Jiang, T ^a   Yang, S S ^a   Yang, Y ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer's disease; anti diabetic drug; dementia; glucose metabolism

Indexed keywords

GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; PIOGLITAZONE; PROTEIN KINASE B; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HIPPOCAMPUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; RAT; TREATMENT DURATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; THIAZOLIDINEDIONES;

EID: 84876464372     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1333277     Document Type: Article

References (30)

1. Yang W., Lu J., Weng J. et al. Prevalence of diabetes among men and women in China. N Engl J Med: 2010; 362 1090 1101
2. Alzheimer's Association: 2010;2010 Alzheimer's disease facts and figures. Alzheimers Dement: 2010; 6 158 194
3. Arvanitakis Z., Wilson R. S., Bienias J. L. et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol: 2004; 61 661 666 (Pubitemid 38637681)
4. Xu W. L., Qiu C. X., Wahlin A. et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology: 2004; 63 1181 1186 (Pubitemid 39350014)
5. de la Monte S. M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs: 2012; 72 49 66
6. Plaschke K., Kopitz J., Siegelin M. et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis: 2010; 19 691 704
7. Belgardt B. F., Bruning J. C. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci: 2010; 1212 97 113
8. Craft S., Peskind E., Schwartz M. W. et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology: 1998; 50 164 168
9. Laron Z. Insulin and the brain. Arch Physiol Biochem: 2009; 115 112 116
10. Park C. R., Seeley R. J., Craft S. et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav: 2000; 68 509 514 (Pubitemid 30129236)
11. Wang X., Zheng W., Xie J. W. et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener: 2010; 5 46
12. Talbot K., Wang H. Y., Kazi H. et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest: 2012; 122 1316 1338
13. de la Monte S. M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res: 2012; 9 35 66
14. Williamson R., McNeilly A., Sutherland C. Insulin resistance in the brain: an old-age or new-age problem? Biochem Pharmacol: 2012; 84 737 745
15. Li X., Pan W., Yang G. Z. et al. Proteome analysis of differential protein expression in brain of rats with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes: 2011; 119 265 270
16. Qian W., Shi J., Yin X. et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis: 2010; 19 1221 1229
17. Zhang X. J., Yang S. S., Zhang M. X. Common pathogenesis of type 2 diabetes and Alzheimer's disease: a potential mechanism. Chin J Pathophysiol: 2010; 26 1107 1114
18. Sato T., Hanyu H., Hirao K. et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging: 2011; 32 1626 1633
19. Kanazawa I., Yamamoto M., Yamaguchi T. et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes: 2011; 119 362 365
20. Dorafshar A. H., Moodley K., Khoe M. et al. Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. Diab Vasc Dis Res: 2010; 7 20 27
21. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem: 1969; 6 24 27
22. Matthews D. R., Hosker J. P., Rudenski A. S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: 1985; 28 412 419 (Pubitemid 15018832)
23. Höistad M., Samskog J., Jacobsen K. X. et al. Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res: 2005; 1041 167 180
24. Leavens K. F., Birnbaum M. J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol: 2011; 46 200 215
25. Hu S. H., Yang Y., Ai D. Y. Tau protein phosphorylation levels and glycogen synthase kinase-3β activities were increased in hippocampus of rats with type 1 or type 2 diabetes. Basic Clinic Med: 2007; 27 1001 1005
26. Panunti B., Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol: 2006; 45 29 35 (Pubitemid 43963483)
27. Srinivasan K., Patole P. S., Kaul C. L. et al. Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol: 2004; 26 327 333 (Pubitemid 38954807)
28. Teramoto T., Yamada N., Shirai K. et al. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. J Atheroscler Thromb: 2007; 14 86 93
29. Pavo I., Jermendy G., Varkonyi T. T. et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab: 2003; 88 1637 1645 (Pubitemid 36623381)
30. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J: 2002; 49 323 328 (Pubitemid 34832304)